Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Neal Katz

Neal Katz

Director of Solutions Marketing

Connect with Neal Katz on LinkedIn
Website:

About the author:

Neal Katz has over 20 years of experience bringing information technology solutions to market. As Senior Manager of Solutions Marketing at Elsevier, Neal has been responsible for assembling information solutions for life science companies, as well as academic and government institutions. He has developed similar solutions and programs at companies like AT&T and Intel.


Posts by Neal Katz

Big Talks on Big Data are Coming to Bio IT World

Posted on May 9th, 2018 in Pharma R&D

At next week’s Bio IT World conference and expo (Boston, May 15-17), Elsevier will be giving four talks on the implications of AI and machine learning on life science research, a statistical analysis of concordance between animal toxicities and human adverse events, strategies for increasing data sharing and the latest technologies being used to integrate multiple data sources. Continue reading “Big Talks on Big Data are Coming to Bio IT World” »

To streamline early discovery, a cross-disciplinary, data-driven workflow process is key

Posted on February 23rd, 2018 in Pharma R&D

“Complex” is the term that best describes the conditions that affect us. Whether it’s a disease or a consequence of a natural process such as aging, there are no simple fixes. Continue reading “To streamline early discovery, a cross-disciplinary, data-driven workflow process is key” »

Taking a Balanced Approach to Monitoring Literature

Posted on September 11th, 2017 in Pharmacovigilance

In a time when the focus on pharmacovigilance is greater than ever before, literature monitoring presents pharmaceutical companies with significant challenges. Pharmacovigilance groups are looking for ways to efficiently and cost-effectively manage an increasing workload while remaining compliant with regulatory best practices. Continue reading “Taking a Balanced Approach to Monitoring Literature” »

Combining Data to Find New Indications, Develop New Targets & Predict Adverse Events

Posted on August 21st, 2017 in Pharma R&D

High-quality compound bioactivity data and information about biological pathways and potential drug targets is more readily available than ever—and in enormous amounts that are often daunting to researchers Continue reading “Combining Data to Find New Indications, Develop New Targets & Predict Adverse Events” »

  1. 1
  2. 2
  3. 3
  4. 4